Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tegaserod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 known ✓ | Q13639 | 1/20 | 0.61 |
| ▸ | HTR1A | P08908 | 5/20 | 0.70 |
| ▸ | HTR2C | P28335 | 5/20 | 0.70 |
| ▸ | HTR1D | P28221 | 3/20 | 0.70 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.70 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.70 |
| ▸ | DRD2 | P14416 | 2/20 | 0.70 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.70 |
| ▸ | DRD4 | P21917 | 2/20 | 0.70 |
| ▸ | HTR2A | P28223 | 2/20 | 0.70 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.70 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.70 |
| ▸ | DRD3 | P35462 | 2/20 | 0.70 |
| ▸ | HTR2B | P41595 | 2/20 | 0.70 |
| ▸ | HTR3A | P46098 | 2/20 | 0.70 |
| ▸ | HTR5A | P47898 | 2/20 | 0.70 |
| ▸ | HTR6 | P50406 | 2/20 | 0.70 |
| ▸ | USP2 | O75604 | 1/20 | 0.70 |
| ▸ | DRD5 | P21918 | 1/20 | 0.70 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tegaserod SCHEMBL4158807 | 1.00 | HTR1A (0.70) | HTR1AHTR2CHTR1DADRB1ADRB3 | |
| Tegaserod SCHEMBL20362149 | 1.00 | HTR1A (0.70) | HTR1AHTR2CHTR1DADRB1ADRB3 | |
| Tegaserod SCHEMBL1042179 | 1.00 | HTR1A (0.70) | HTR1AHTR2CHTR1DADRB1ADRB3 | |
| Tegaserod SCHEMBL3893820 | 1.00 | HTR1A (0.70) | HTR1AHTR2CHTR1DADRB1ADRB3 | |
| Tegaserod SCHEMBL4643931 | 0.99 | HTR1A (0.69) | HTR1AHTR2CHTR1DADRB1ADRB3 | |
| Tegaserod SCHEMBL3229259 | 0.95 | HTR1A (0.63) | HTR1AHTR2CHTR1DADRB1ADRB3 | |
| Tegaserod SCHEMBL3892146 | 0.95 | HTR1A (0.63) | HTR1AHTR2CHTR1DADRB1ADRB3 | |
| Tegaserod SCHEMBL4637068 | 0.95 | HTR1A (0.62) | HTR1AHTR2CHTR1DADRB1ADRB3 | |
| Tegaserod SCHEMBL4636808 | 0.95 | HTR1A (0.62) | HTR1AHTR2CHTR1DADRB1ADRB3 | |
| Tegaserod SCHEMBL16464 | 0.94 | HTR1A (0.67) | HTR1AHTR2CHTR1DADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2095 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12364682-B2 | Use of tegaserod in preparation of anti-tumor drug | QINGDAO HAIJI BIOMEDICINE CO., LTD. (CN) | 2025-07-22 | — | — | US | claimed |
| EP-4536236-A2 | METHODS OF MODULATING ATXN2 EXPRESSION | University of Utah Research Foundation (US) | 2025-04-16 | — | — | EP | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| US-20240050440-A1 | THERAPEUTIC TARGETS AND AGENTS FOR THE TREATMENT OF TRIOSEPHOSPHATE ISOMERASE (TPI) DEFICIENCY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-02-15 | — | — | US | claimed |
| WO-2023239747-A2 | METHODS OF MODULATING ATXN2 EXPRESSION | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2023-12-14 | — | — | WO | claimed |
| CN-117017982-A | Application of tegaserod maleate in treating prostate tumor | 杭州开泰生物技术有限公司 | 2023-11-10 | — | — | CN | claimed |
| WO-2022151532-A1 | APPLICATION OF TEGASEROD MALEATE IN TREATMENT OF ACUTE MYELOCYTIC LEUKEMIA AND COLORECTAL CANCER | 陈璋辉 | 2022-07-21 | — | — | WO | claimed |
| CN-114762685-A | Application of tegaserod maleate in treating acute myeloid leukemia and colorectal cancer | 陈璋辉 | 2022-07-19 | — | — | CN | claimed |
| US-20220218666-A1 | APPLICATION OF TEGASEROD IN PREPARATION OF ANTI-TUMOR DRUG | MARINE BIOMEDICAL RESEARCH INSTITUTE OF QINGDAO CO., LTD. (CN) | 2022-07-14 | — | — | US | claimed |
| WO-2022147217-A1 | THERAPEUTIC TARGETS AND AGENTS FOR THE TREATMENT OF TRIOSEPHOSPHATE ISOMERASE (TPI) DEFICIENCY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-07-07 | — | — | WO | claimed |
| CN-1176077-C | Tegaserod maleate-water crystal | 江苏省药物研究所 | 2004-11-17 | — | — | CN | claimed |
| CN-1543946-A | Oral preparation of Tegaserod or its acid salt and its preparing process | 孟凡清 | 2004-11-10 | — | — | CN | claimed |
| WO-2004087135-A1 | ORAL SUSPENSION OF TEGASEROD | NOVARTIS AG (CH) | 2004-10-14 | — | — | WO | claimed |
| WO-2004085393-A1 | NOVEL CRYSTALLINE FORMS OF TEGASEROD MALEATE | HETERO DRUGS LIMITED (IN) | 2004-10-07 | — | — | WO | claimed |
| CN-1167415-C | Orally applied solid preparation of medicine difficult to dissolve | 中国人民解放军军事医学科学院毒物药 | 2004-09-22 | — | — | CN | claimed |
| CN-1528293-A | Tegaserod maleate drop pill and preparing method thereof | 南昌弘益科技有限公司 | 2004-09-15 | — | — | CN | claimed |
| CN-1452962-A | Medicine composition of maleic acid and Tegaserod and its prepn | WANGQUAN YANGGUANG MEDICINE SC (CN) | 2003-11-05 | — | — | CN | claimed |
| CN-1443535-A | Tegasevod maleate oral preparation and its preparation process-for curing intestinal irritability syndrome | NANCHANG HONGYI SCIENCE & TECH (CN) | 2003-09-24 | — | — | CN | claimed |
| CN-1425651-A | Tegaserod maleate-water crystal | JIANGSU PROV MEDICINE INST (CN) | 2003-06-25 | — | — | CN | claimed |
| CN-1305806-A | Orally applied solid preparation of medicine difficult to dissolve | INST OF TOXIC MEDICINE PLA ACA (CN) | 2001-08-01 | — | — | CN | claimed |